• Consensus Rating: Buy
  • Consensus Price Target: $7.33
  • Forecasted Upside: 184.24 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$2.58
▼ -0.01 (-0.39%)

This chart shows the closing price for IFRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New InflaRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IFRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IFRX

Analyst Price Target is $7.33
▲ +184.24% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for InflaRx in the last 3 months. The average price target is $7.33, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 184.24% upside from the last price of $2.58.

This chart shows the closing price for IFRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in InflaRx. This rating has held steady since September 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/8/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/6/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/5/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/5/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/3/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2022

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2022Raymond JamesBoost TargetStrong-Buy$7.00 ➝ $8.00Low
11/9/2022SVB LeerinkReiterated RatingOutperformLow
8/8/2022HC WainwrightBoost TargetBuy$7.00 ➝ $8.00Low
5/13/2022Raymond JamesLower Target$15.00 ➝ $7.00Low
5/13/2022HC WainwrightLower Target$10.00 ➝ $7.00Low
3/25/2022SVB LeerinkLower TargetOutperform$8.00 ➝ $6.00Low
2/28/2022GuggenheimDowngradeBuy ➝ NeutralHigh
11/8/2021Raymond JamesBoost TargetStrong-Buy$14.00 ➝ $15.00Low
10/27/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$10.00 ➝ $14.00High
10/14/2021SVB LeerinkReiterated RatingBuyLow
8/6/2021Raymond JamesLower TargetOutperform$11.00 ➝ $10.00Low
8/6/2021Credit Suisse GroupLower TargetUnderperform$2.80 ➝ $2.50Medium
5/19/2021SVB LeerinkReiterated RatingBuy$6.00Low
5/13/2021Credit Suisse GroupLower TargetUnderperform$3.50 ➝ $2.80High
5/13/2021Raymond JamesLower TargetOutperform$12.00 ➝ $11.00High
3/26/2021HC WainwrightLower TargetBuy$12.00 ➝ $10.00Low
3/11/2021GuggenheimUpgradeNeutral ➝ Buy$16.00High
1/13/2021HC WainwrightReiterated RatingBuyMedium
1/7/2021HC WainwrightBoost TargetBuy$11.00 ➝ $12.00N/A
11/6/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$7.00 ➝ $10.00Low
10/30/2020Lifesci CapitalReiterated RatingMarket PerformLow
10/8/2020HC WainwrightInitiated CoverageBuy$11.00Medium
9/14/2020Ci CapitalReiterated RatingHold$7.00High
7/31/2020Raymond JamesLower TargetOutperform$20.00 ➝ $19.00High
6/17/2020Raymond JamesReiterated RatingBuyMedium
6/16/2020BTIG ResearchInitiated CoverageBuy$12.00High
5/28/2020Ci CapitalReiterated RatingHold$7.00Medium
5/21/2020BMO Capital MarketsBoost TargetMarket Perform$4.00 ➝ $7.00Medium
5/21/2020Raymond JamesBoost TargetOutperform$10.00 ➝ $20.00High
5/7/2020SVB LeerinkBoost TargetHold$4.00 ➝ $7.00Low
4/29/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$10.00High
7/19/2019Raymond JamesReiterated RatingHoldN/A
6/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
6/5/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
6/5/2019Credit Suisse GroupDowngradeOutperform ➝ UnderperformHigh
6/5/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00High
6/5/2019SunTrust BanksDowngradeBuy ➝ Hold$55.00 ➝ $5.00High
6/5/2019Robert W. BairdDowngradeOutperform ➝ Neutral$58.00 ➝ $6.00High
6/5/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$67.00 ➝ $9.00High
6/5/2019GuggenheimDowngradeBuy ➝ Neutral$65.00 ➝ $6.00High
5/24/2019Raymond JamesSet TargetBuy$44.00Medium
4/24/2019BMO Capital MarketsBoost TargetOutperform$64.00High
3/29/2019Robert W. BairdLower TargetOutperform ➝ Outperform$62.00 ➝ $58.00High
2/22/2019GuggenheimInitiated CoverageBuy$65.00Low
2/5/2019JPMorgan Chase & Co.Boost TargetOverweight ➝ Top Pick$42.00 ➝ $65.00High
1/28/2019Robert W. BairdInitiated CoverageOutperform$62.00High
12/10/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$47.00Low
7/13/2018BMO Capital MarketsInitiated CoverageOutperform$45.00Medium
6/28/2018Raymond JamesInitiated CoverageOutperform$44.00High
6/28/2018SunTrust BanksInitiated CoverageBuy$55.00High
5/18/2018SVB LeerinkReiterated RatingOutperform$42.00Low
4/2/2018SVB LeerinkBoost TargetOutperform$31.00 ➝ $36.00Low
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$40.00Low
12/4/2017BMO Capital MarketsInitiated CoverageOutperform$31.00High
12/4/2017SVB LeerinkInitiated CoverageOutperform$31.00High
12/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$30.00High
(Data available from 11/30/2017 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/4/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/3/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
7/3/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
8/2/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
10/1/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
InflaRx logo
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Read More

Today's Range

Now: $2.58
Low: $2.53
High: $2.58

50 Day Range

MA: $2.51
Low: $2.12
High: $2.73

52 Week Range

Now: $2.58
Low: $0.78
High: $5.40

Volume

471 shs

Average Volume

76,725 shs

Market Capitalization

$114.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of InflaRx?

The following sell-side analysts have issued research reports on InflaRx in the last year: Guggenheim, HC Wainwright, Raymond James, and SVB Leerink LLC.
View the latest analyst ratings for IFRX.

What is the current price target for InflaRx?

3 Wall Street analysts have set twelve-month price targets for InflaRx in the last year. Their average twelve-month price target is $7.33, suggesting a possible upside of 184.2%. Raymond James has the highest price target set, predicting IFRX will reach $8.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $6.00 for InflaRx in the next year.
View the latest price targets for IFRX.

What is the current consensus analyst rating for InflaRx?

InflaRx currently has 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IFRX will outperform the market and that investors should add to their positions of InflaRx.
View the latest ratings for IFRX.

What other companies compete with InflaRx?

How do I contact InflaRx's investor relations team?

InflaRx's physical mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company's listed phone number is 493641508180 and its investor relations email address is [email protected] The official website for InflaRx is www.inflarx.de. Learn More about contacing InflaRx investor relations.